Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019. https://doi.org/10.1038/s41572-019-0079-y.

Article  PubMed  Google Scholar 

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015. https://doi.org/10.1016/S1474-4422(15)00145-3.

Article  PubMed  Google Scholar 

Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021. https://doi.org/10.1016/j.autrev.2020.102712.

Article  PubMed  Google Scholar 

Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016. https://doi.org/10.1056/NEJMra1602678.

Article  PubMed  Google Scholar 

Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016. https://doi.org/10.1212/WNL.0000000000002790.

Article  PubMed  PubMed Central  Google Scholar 

Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017. https://doi.org/10.1002/mus.25597.

Article  PubMed  Google Scholar 

Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016. https://doi.org/10.1002/acn3.314.

Article  PubMed  PubMed Central  Google Scholar 

Robeson KR, Kumar A, Keung B, et al. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis. JAMA Neurol. 2017. https://doi.org/10.1001/jamaneurol.2016.4190.

Article  PubMed  Google Scholar 

Li T, Zhang G, Li Y, et al. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. J Clin Neurosci. 2021. https://doi.org/10.1016/j.jocn.2020.11.043.

Article  PubMed  Google Scholar 

Feng X, Song Z, Wu M, et al. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Front Neurol. 2021. https://doi.org/10.3389/fneur.2021.725700.

Article  PubMed  PubMed Central  Google Scholar 

Zhao C, Pu M, Chen D, et al. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol. 2021. https://doi.org/10.3389/fneur.2021.736190.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/bmj.n71.

Fei F. Clinical observation of rituximab combined with bromopyrimethamine in the treatment of myasthenia gravis. Chin J Hemorheol. 2020. https://doi.org/10.3969/j.issn.1009-881X.2020.02.012.

Article  Google Scholar 

Anning L. Effects of rituximab on drug-resistant myasthenia gravis. Health Lit. 2022;67–9.

Jiexi W. Analysis of the clinical efficacy of rituximab in myasthenia gravis treatment. Chin J Neuroimmunol Neurol. 2020;27(1):5.

Google Scholar 

Sijia Z. The Clinical Observation of RTX Treating Myasthenia Gravis. Air Force Medical University. 2018.

Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0851.

Article  PubMed  PubMed Central  Google Scholar 

Afanasiev V, Demeret S, Bolgert F, et al. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord. 2017. https://doi.org/10.1016/j.nmd.2016.12.004.

Article  PubMed  Google Scholar 

Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022. https://doi.org/10.1001/jamaneurol.2022.2887

Litchman T, Roy B, Kumar A, et al. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. J Neurol Sci. 2020. https://doi.org/10.1016/j.jns.2020.116690.

Article  PubMed  Google Scholar 

Nelke C, Schroeter CB, Stascheit F et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022. https://doi.org/10.1136/jnnp-2021-328665.

Jing S, Lu J, Song J, et al. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol. 2019. https://doi.org/10.1016/j.jneuroim.2019.05.004.

Article  PubMed  Google Scholar 

Göl MF, Kara F, Boz M et al. Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey. Ideggyógyászati Szemle 2022. https://doi.org/10.18071/isz.75.0351.

Dos Santos A, Noury JB, Genestet S, et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14391.

Article  PubMed  Google Scholar 

Landon-Cardinal O, Friedman D, Guiguet M, et al. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. J Neuromuscul Dis. 2018. https://doi.org/10.3233/JND-180300.

Article  PubMed  Google Scholar 

Zhang C, Bu B, Yang H, et al. Immunotherapy choice and maintenance for generalized myasthenia gravis in China. CNS Neurosci Ther. 2020. https://doi.org/10.1111/cns.13468.

Article  PubMed  PubMed Central  Google Scholar 

Cortés Vicente E, Rojas Garcia R, DíazManera J, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol. 2018. https://doi.org/10.1002/acn3.564.

Article  PubMed  PubMed Central  Google Scholar 

Du Y, Li C, Hao Y, et al. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis. J Neurol. 2022. https://doi.org/10.1007/s00415-022-11048-4.

Article  PubMed  Google Scholar 

Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012. https://doi.org/10.1212/WNL.0b013e3182407982.

Article  PubMed  Google Scholar 

Chan F, Swayne A, Gillis D et al. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. J Neurol Neurosurg Psychiatry. 2019. https://doi.org/10.1136/jnnp-2018-319410.

Castiglione JI, Rivero AD, Barroso F, et al. Long-term remission with low-dose rituximab in myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis. 2022. https://doi.org/10.1097/CND.0000000000000420.

Article  PubMed  Google Scholar 

Lu J, Zhong H, Jing S, et al. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis. Muscle Nerve. 2020. https://doi.org/10.1002/mus.26790.

Article  PubMed  Google Scholar 

Zhong H, Lu J, Jing S, et al. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. J Neuroimmunol. 2020. https://doi.org/10.1016/j.jneuroim.2020.577383.

Article  PubMed  Google Scholar 

Li H, Huang Z, Jia D, et al. Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol. 2021. https://doi.org/10.1016/j.jneuroim.2021.577528.

Article  PubMed  PubMed Central  Google Scholar 

Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology. 2022. https://doi.org/10.1212/WNL.0000000000013121.

Article  PubMed  PubMed Central  Google Scholar 

Choi K, Hong Y, Ahn S, et al. Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis. Ther Adv Neurol Disord. 2019. https://doi.org/10.1177/1756286419871187.

Article  PubMed  PubMed Central  Google Scholar 

Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011. https://doi.org/10.1177/1756285611411503.

Article  PubMed  PubMed Central  Google Scholar 

Doughty CT, Suh J, David WS, Amato AA, Guidon AC. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. Muscle Nerve. 2021.